Research progress on perioperative management of tooth extraction in denosumab-treated patients
10.3760/cma.j.cn112144-20240427-00168
- VernacularTitle:地舒单抗用药人群拔牙围手术期管理的研究进展
- Author:
Zhishen JIANG
1
;
Yubin CAO
;
Zhiwei CAO
;
Li YE
;
Jiyuan LIU
;
Jian PAN
Author Information
1. 四川大学华西口腔医院口腔颌面外科 口腔疾病防治全国重点实验室 国家口腔医学中心 国家口腔疾病临床医学研究中心，成都 610041
- Keywords:
Tooth extraction;
Denosumab;
Bisphosphonate;
Osteonecrosis of the jaw;
Antibiotics
- From:
Chinese Journal of Stomatology
2024;59(8):840-845
- CountryChina
- Language:Chinese
-
Abstract:
Denosumab, a human monoclonal antibody, is used for the prevention of malignant tumor-related bone events and the treatment of osteoporosis with high fracture risk. Since its approval in China in 2019, denosumab-related osteonecrosis of the jaw (DRONJ) has attracted increasing attention. DRONJ, similar to bisphosphonate-related osteonecrosis of the jaw, often occurs after tooth extraction and manifests as exposed bone necrosis, purulent discharge, facial swelling and pain, severely impacting patients′ quality of life. However, the perioperative management strategies for DRONJ differ from those for bisphosphonate-related osteonecrosis of the jaw. This article summarizes the perioperative management strategies for high-risk DRONJ patients from aspects such as oral hygiene care, antibiotic use, drug discontinuation during the perioperative period, and surgical strategy selection, aiming to provide guidance for oral surgeons in managing tooth extraction in denosumab-treated patients.
